0
Letters |

Sodium Bicarbonate vs Sodium Chloride in Preventing Contrast Medium–Induced Nephropathy

William Burgess, MD, PhD; Gregory J. Merten, MD; Robert A. Rittase, PharmD
JAMA. 2009;301(4):377-380. doi:10.1001/jama.2009.16
Text Size: A A A
Published online

To the Editor: In their randomized trial comparing sodium bicarbonate vs sodium chloride for prevention of contrast medium–induced nephropathy (CIN), Dr Brar and colleagues1 used a lower dose of bicarbonate than described in other studies2 4 and found that this lower dose of bicarbonate was inadequate to significantly reduce CIN. Their study did not document urine pH as was done in other studies.2 3 ,5 The bicarbonate concentration in their study was 130 mEq/L compared with 154 mEq/L in the other studies. The administered dose of bicarbonate anion was higher in the studies by Merten et al2 (by 18%), Ozcan et al3 (by 58%), and Recio-Mayoral et al4 (by 202%). The higher doses would likely result in a higher urine pH, although the bicarbonate effect on urine pH is nonlinear.

The hypothesis set forth in the original bicarbonate hydration article2 referred to the establishment of a relatively neutral pH in the medullary portion of the kidney prior to contrast exposure with its subsequent complex cascade of events leading to free radical formation and CIN. A study in children by Assadi5 suggests that even the dose of bicarbonate used by Merten et al may well have been less than optimal, with the urine pH in this pediatric study correlating inversely with CIN. The cohort of 46 children (mean weight, 44 kg; mean serum creatinine level, 1.43 mg/dL) with higher urine pH (7.8) resulting from acetazolamide administration had a 0% incidence of CIN compared with the randomized cohort of 50 children receiving the protocol used by Merten et al (urine pH, 6.4; CIN incidence, 8.7%; P = .049). The study by Merten et al reported a urine pH of 6.5.

Despite the lower bicarbonate dose, the study by Brar et al did show that the majority of outcome measures were improved with bicarbonate, but these results were not statistically significant. The outcome of CIN in 21 patients with the highest risk (estimated glomerular filtration rate ≤30 mL/min per 1.73 m2) was 36% in the bicarbonate group compared with 20% in the saline group (P = .64). A larger sample size may have resulted in a statistically significant difference.

Future studies that use bicarbonate hydration should include an outcome measure of the effectiveness of the bicarbonate dose (urine pH) and use an adequate alkalinizing dose to achieve a neutral urine pH.

AUTHOR INFORMATION

Financial Disclosures: Dr Burgess reported that US patent No. 7,019,035 B2 was issued to him on March 28, 2006, and assigned to MD Scientific LLC, in which he has minority ownership. This patent is for a method for sodium bicarbonate prophylaxis to prevent CIN. The other authors reported no disclosures.

REFERENCES

Brar SS, Shen AY, Jorgensen MB,  et al.  Sodium bicarbonate vs sodium chloride for the prevention of contrast medium–induced nephropathy in patients undergoing coronary angiography.  JAMA. 2008;300(9):1038-1046
PubMedCrossRef
Merten GJ, Burgess WP, Gray LV,  et al.  Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial.  JAMA. 2004;291(19):2328-2334
PubMedCrossRef
Ozcan EE, Guneri S, Akdeniz B,  et al.  Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy: a comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures: a single-center prospective controlled trial.  Am Heart J. 2007;154(3):539-544
PubMedCrossRef
Recio-Mayoral A, Chaparro M, Prado B,  et al.  The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study.  J Am Coll Cardiol. 2007;49(12):1283-1288
PubMedCrossRef
Assadi F. Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug.  Pediatr Cardiol. 2006;27(2):238-242
PubMedCrossRef

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Brar SS, Shen AY, Jorgensen MB,  et al.  Sodium bicarbonate vs sodium chloride for the prevention of contrast medium–induced nephropathy in patients undergoing coronary angiography.  JAMA. 2008;300(9):1038-1046
PubMedCrossRef
Merten GJ, Burgess WP, Gray LV,  et al.  Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial.  JAMA. 2004;291(19):2328-2334
PubMedCrossRef
Ozcan EE, Guneri S, Akdeniz B,  et al.  Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy: a comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures: a single-center prospective controlled trial.  Am Heart J. 2007;154(3):539-544
PubMedCrossRef
Recio-Mayoral A, Chaparro M, Prado B,  et al.  The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study.  J Am Coll Cardiol. 2007;49(12):1283-1288
PubMedCrossRef
Assadi F. Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug.  Pediatr Cardiol. 2006;27(2):238-242
PubMedCrossRef
January 28, 2009
Bradley D. Shy, MD; Amit Gupta, MD; Robert S. Hoffman, MD
JAMA. 2009;301(4):377-380.
January 28, 2009
Mehmet Kanbay, MD; Benan Kasapoglu, MD; Ali Akcay, MD
JAMA. 2009;301(4):377-380.
January 28, 2009
Alberto Bouzas-Mosquera, MD; José M. Vázquez-Rodríguez, MD; Jesús Peteiro, MD, PhD
JAMA. 2009;301(4):377-380.
January 28, 2009
Somjot S. Brar, MD; Albert Yuh-Jer Shen, MD; Michael B. Jorgensen, MD
JAMA. 2009;301(4):377-380.
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.